The Effect of Combination of Mosapride and DPP-4 Inhibitor on Plasma Concentration of Incretin Hormones
Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to investigate the effects of combined administration of mosapride
as modulator of gastrointestinal motility and DPP-4 inhibitor on secretion of gut hormone
such as glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP), and oral
glucose tolerance. Additionally, change in lipid profile and insulin secretion will be also
assessed.